300765 石药创新
已收盘 11-06 15:00:00
资讯
新帖
简况
石药创新:目前公司生产经营一切正常
证券之星 · 11-07 13:27
石药创新:目前公司生产经营一切正常
石药创新:截至2026年10月30日股东数为27,467户
证券之星 · 11-07 13:24
石药创新:截至2026年10月30日股东数为27,467户
石药创新(300765.SZ)控股子公司SYS6062启动Ⅰ/Ⅱ期临床试验
智通财经 · 11-05 16:52
石药创新(300765.SZ)控股子公司SYS6062启动Ⅰ/Ⅱ期临床试验
石药创新(300765)11月3日主力资金净卖出2899.22万元
证券之星 · 11-04
石药创新(300765)11月3日主力资金净卖出2899.22万元
石药创新(300765.SZ)子公司SYS6088启动Ⅰ/Ⅱ期临床试验
智通财经 · 11-03
石药创新(300765.SZ)子公司SYS6088启动Ⅰ/Ⅱ期临床试验
石药创新(300765)11月2日主力资金净卖出407.96万元
证券之星 · 11-03
石药创新(300765)11月2日主力资金净卖出407.96万元
股市必读:石药创新(300765)10月30日董秘有最新回复
证券之星 · 11-02
股市必读:石药创新(300765)10月30日董秘有最新回复
10月30日石药创新创60日新低,汇添富创新医药混合A基金重仓该股
证券之星 · 10-30
10月30日石药创新创60日新低,汇添富创新医药混合A基金重仓该股
石药创新:截至2026年10月20日,公司合并普通账户和融资融券信用账户股东数为27,521户
证券之星 · 10-30
石药创新:截至2026年10月20日,公司合并普通账户和融资融券信用账户股东数为27,521户
股市必读:石药创新三季报 - 第三季度单季净利润同比下降140.95%
证券之星 · 10-30
股市必读:石药创新三季报 - 第三季度单季净利润同比下降140.95%
石药创新:第七届董事会第五次会议决议公告
同花顺 · 10-28
石药创新:第七届董事会第五次会议决议公告
石药集团:石药创新前三季度归母净利润12.1亿元
同花顺 · 10-28
石药集团:石药创新前三季度归母净利润12.1亿元
10月27日石药创新跌11.21%,工银前沿医疗股票A基金重仓该股
证券之星 · 10-27
10月27日石药创新跌11.21%,工银前沿医疗股票A基金重仓该股
10月26日石药创新跌5.81%,鹏华医疗保健股票基金重仓该股
证券之星 · 10-26
10月26日石药创新跌5.81%,鹏华医疗保健股票基金重仓该股
【机构调研记录】汇添富基金调研石药创新、迈普医学
证券之星 · 10-23
【机构调研记录】汇添富基金调研石药创新、迈普医学
石药创新:控股子公司SYS6043启动III期临床试验
同花顺 · 10-22
石药创新:控股子公司SYS6043启动III期临床试验
10月22日石药创新跌5.40%,工银前沿医疗股票A基金重仓该股
证券之星 · 10-22
10月22日石药创新跌5.40%,工银前沿医疗股票A基金重仓该股
石药创新:关于变更持续督导保荐代表人的公告
同花顺 · 10-21
石药创新:关于变更持续督导保荐代表人的公告
10月20日石药创新涨7.99%,工银前沿医疗股票A基金重仓该股
证券之星 · 10-20
10月20日石药创新涨7.99%,工银前沿医疗股票A基金重仓该股
石药创新(300765)10月15日主力资金净卖出223.63万元
证券之星 · 10-16
石药创新(300765)10月15日主力资金净卖出223.63万元
暂无数据
公司概况
公司名称:
石药创新制药股份有限公司
所属行业:
食品制造业
上市日期:
2019-03-22
主营业务:
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格:
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":34.65,"timestamp":1793948619000,"preClose":35.84,"halted":0,"volume":13454377,"delay":0,"changeRate":-0.0332,"floatShares":1405000000,"shares":1405000000,"eps":0.7069,"marketStatus":"已收盘","change":-1.19,"latestTime":"11-06 15:00:00","open":34.51,"high":36.25,"low":34.45,"amount":474000000,"amplitude":0.0502,"askPrice":34.66,"askSize":8,"bidPrice":34.65,"bidSize":864,"shortable":0,"etf":0,"ttmEps":0.7069,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":35.84,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":39.42,"lowLimit":32.26,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":12.95,"roa":"--","peRate":49.016834,"roe":"36.91%","epsLYR":-0.1731,"committee":0.563014,"marketValue":48669000000,"turnoverRate":0.0096,"status":1,"floatMarketCap":48669000000},"requestUrl":"/m/hq/s/300765/tweets","defaultTab":"tweets","newsList":[{"id":"2681581935","title":"石药创新:目前公司生产经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2681581935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681581935?lang=zh_cn&edition=full","pubTime":"2026-11-07 13:27","pubTimestamp":1794029231,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问最近公司股价连续大跌,公司是否营业正常,是否有应该披露而没有披露的信息?石药创新回复:您好,感谢您对公司的关注。目前公司生产经营一切正常,各项业务有序推进。公司严格遵守信息披露相关法律法规,不存在应披露而未披露的重大信息。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700013294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681819331","title":"石药创新:截至2026年10月30日股东数为27,467户","url":"https://stock-news.laohu8.com/highlight/detail?id=2681819331","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681819331?lang=zh_cn&edition=full","pubTime":"2026-11-07 13:24","pubTimestamp":1794029057,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问公司截止10.31日最新股东户数是多少?谢谢石药创新回复:您好,感谢您对公司的关注,截至2026年10月30日,公司合并普通账户和融资融券信用账户股东数为27,467户,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700013271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681044602","title":"石药创新(300765.SZ)控股子公司SYS6062启动Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2681044602","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681044602?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:52","pubTimestamp":1793868778,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新(300765.SZ)发布公告,公司的控股子公司石药集团巨石生物制药有限公司(以下简称“巨石生物”)已于近日启动评价SYS6062在晚期实体瘤患者中的安全性、耐受性、药代动力学(PK)特征和有效性的剂量递增、PK扩展和队列扩展I/II期临床试验。SYS6062是巨石生物研发的靶向癌胚抗原相关细胞黏附分子5(CEACAM5)的抗体偶联药物(ADC),其抗体部分可特异性结合到表达CEACAM5的肿瘤细胞表面并内化入细胞,经蛋白酶特异性剪切后释放小分子毒素,从而杀伤肿瘤细胞,且可发挥旁观者效应非特异性杀伤周围肿瘤组织细胞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BMED","IBBJ","IBBQ","PSYK","MDTX","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680707119","title":"石药创新(300765)11月3日主力资金净卖出2899.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680707119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680707119?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:05","pubTimestamp":1793757954,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月3日收盘,石药创新报收于29.73元,下跌6.83%,换手率1.19%,成交量16.66万手,成交额5.03亿元。11月3日的资金流向数据方面,主力资金净流出2899.22万元,占总成交额5.76%,游资资金净流出2739.11万元,占总成交额5.44%,散户资金净流入5638.33万元,占总成交额11.21%。融券方面,融券卖出2.42万股,融券偿还3.04万股,融券余量7.91万股,融券余额235.14万元。石药创新主营业务:生物制药和功能食品及原料的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400014459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680745601","title":"石药创新(300765.SZ)子公司SYS6088启动Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2680745601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680745601?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:39","pubTimestamp":1793695195,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新 发布公告,公司的控股子公司石药集团巨石生物制药有限公司已于近日启动评价SYS6088在晚期 /转移性实体瘤患者中的安全性、耐受性、药代动力学特征和有效性的剂量递增、PK扩增和队列扩展Ⅰ/Ⅱ期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","BMED","300765","IBBJ","BK0226","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680913790","title":"石药创新(300765)11月2日主力资金净卖出407.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680913790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680913790?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:42","pubTimestamp":1793670132,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月2日收盘,石药创新报收于31.91元,下跌1.36%,换手率1.23%,成交量17.21万手,成交额5.47亿元。11月2日的资金流向数据方面,主力资金净流出407.96万元,占总成交额0.75%,游资资金净流出1336.49万元,占总成交额2.45%,散户资金净流入1744.45万元,占总成交额3.19%。近5日资金流向一览见下表:石药创新融资融券信息显示,融资方面,当日融资买入2285.11万元,融资偿还2729.27万元,融资净偿还444.16万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300014743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680207545","title":"股市必读:石药创新(300765)10月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680207545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680207545?lang=zh_cn&edition=full","pubTime":"2026-11-02 02:28","pubTimestamp":1793557693,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘,石药创新报收于32.35元,下跌7.52%,换手率1.46%,成交量20.46万手,成交额6.84亿元。董秘最新回复投资者: 请问截止2026年10月10日公司的股东人数是多少?谢谢董秘: 您好,感谢您对公司的关注,截至2026年10月9日,公司合并普通账户和融资融券信用账户股东数为30,319户,谢谢!当日关注点交易信息汇总:10月30日主力资金净流出3389.09万元,占总成交额4.95%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200000617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679275296","title":"10月30日石药创新创60日新低,汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679275296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679275296?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:20","pubTimestamp":1793352023,"startTime":"0","endTime":"0","summary":"证券之星消息,10月30日石药创新跌7.52%创60日新低,收盘报32.35元,换手率1.46%,成交量20.46万手,成交额6.84亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共56家,其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000042220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK1574","BK0226","BK1161","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679635295","title":"石药创新:截至2026年10月20日,公司合并普通账户和融资融券信用账户股东数为27,521户","url":"https://stock-news.laohu8.com/highlight/detail?id=2679635295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679635295?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:00","pubTimestamp":1793350838,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问:您好!请问截至10月20日收盘公司股东人数是多少,谢谢!石药创新回复:您好,感谢您对公司的关注,截至2026年10月20日,公司合并普通账户和融资融券信用账户股东数为27,521户,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679923224","title":"股市必读:石药创新三季报 - 第三季度单季净利润同比下降140.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679923224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679923224?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:32","pubTimestamp":1793309569,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年前三季度归母净利润12.1亿元,同比上升5130.83%;但第三季度单季归母净利润为-5132.9万元,同比下降140.95%。2026年第三季度单季度主营收入7.36亿元,同比上升35.47%;单季度归母净利润-5132.9万元,同比下降140.95%;单季度扣非净利润-7380.47万元,同比下降211.72%;负债率47.66%,财务费用4859.33万元,毛利率71.27%。公司公告汇总2026年三季度报告2026年第三季度营业收入7.36亿元,同比增长35.47%;归属于上市公司股东的净利润-5132.9万元,同比减少140.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000007457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678464473","title":"石药创新:第七届董事会第五次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2678464473","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678464473?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:31","pubTimestamp":1793187060,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月28日,石药创新发布公告称,公司于2026年10月27日召开第七届董事会第五次会议,审议通过《关于公司〈2026年第三季度报告〉的议案》《关于部 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681203203.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681203203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678946313","title":"石药集团:石药创新前三季度归母净利润12.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678946313","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678946313?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:28","pubTimestamp":1793183280,"startTime":"0","endTime":"0","summary":"石药集团(01093)发布公告,本公司的附属公司石药创新制药股份有限公司(石药创新)于2026年前三季度取得营业收入39.76亿元,同比增加149.62%;归属于上市公司股东的净利润12.1亿元;基本每股收 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261028/c681199668.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261028/c681199668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678712281","title":"10月27日石药创新跌11.21%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678712281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678712281?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:06","pubTimestamp":1793092004,"startTime":"0","endTime":"0","summary":"证券之星消息,10月27日石药创新跌11.21%,收盘报38.56元,换手率1.81%,成交量25.44万手,成交额10.32亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共41家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678116395","title":"10月26日石药创新跌5.81%,鹏华医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678116395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678116395?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:43","pubTimestamp":1793004228,"startTime":"0","endTime":"0","summary":"证券之星消息,10月26日石药创新跌5.81%,收盘报43.43元,换手率1.93%,成交量27.06万手,成交额11.76亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为鹏华基金的鹏华医疗保健股票。鹏华医疗保健股票目前规模为3.36亿元,最新净值1.974,较上一交易日上涨2.71%,近一年下跌9.82%。鹏华医疗保健股票的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600022116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677325918","title":"【机构调研记录】汇添富基金调研石药创新、迈普医学","url":"https://stock-news.laohu8.com/highlight/detail?id=2677325918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677325918?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:06","pubTimestamp":1792713999,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月22日披露的机构调研信息,汇添富基金近期对2家上市公司进行了调研,相关名单如下:1)石药创新 调研纪要:关于与阿斯利康的合作,特许权使用费费率属于商业保密范畴,未披露具体比例;里程碑收益确认取决于项目进展,存在不确定性,阿斯利康将主导授权区域内的商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0251","300765","301033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677695362","title":"石药创新:控股子公司SYS6043启动III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2677695362","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677695362?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:56","pubTimestamp":1792659360,"startTime":"0","endTime":"0","summary":"人民财讯10月22日电,石药创新(300765)10月22日公告,公司控股子公司巨石生物已于近日启动一项评估SYS6043对比研究者选择的化疗一线治疗不可手术切除的复发或转移性三阴性乳腺癌患者的随机 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261022/c680983503.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261022/c680983503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["PSYK","300765","BK0226","IBBQ","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677582309","title":"10月22日石药创新跌5.40%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677582309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677582309?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:50","pubTimestamp":1792659027,"startTime":"0","endTime":"0","summary":"证券之星消息,10月22日石药创新跌5.40%,收盘报43.99元,换手率1.45%,成交量20.41万手,成交额9.36亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677672777","title":"石药创新:关于变更持续督导保荐代表人的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2677672777","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677672777?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:43","pubTimestamp":1792590180,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月21日,石药创新发布公告称,公司于近日收到国投证券股份有限公司《关于变更石药创新制药股份有限公司持续督导保荐代表人的通知》。栗灵芝女 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261021/c680947853.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261021/c680947853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676566563","title":"10月20日石药创新涨7.99%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676566563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676566563?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:33","pubTimestamp":1792485180,"startTime":"0","endTime":"0","summary":"证券之星消息,10月20日石药创新涨7.99%,收盘报47.3元,换手率1.71%,成交量24.04万手,成交额11.16亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000024603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675512715","title":"石药创新(300765)10月15日主力资金净卖出223.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675512715","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675512715?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:08","pubTimestamp":1792112937,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月15日收盘,石药创新报收于42.98元,下跌0.35%,换手率0.67%,成交量9.4万手,成交额4.06亿元。10月15日的资金流向数据方面,主力资金净流出223.63万元,占总成交额0.55%,游资资金净流出495.08万元,占总成交额1.22%,散户资金净流入718.72万元,占总成交额1.77%。融券方面,融券卖出300.0股,融券偿还5100.0股,融券余量11.41万股,融券余额490.59万元。石药创新主营业务:生物制药和功能食品及原料的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794112386414,"stockEarnings":[{"period":"1week","weight":0.0711},{"period":"1month","weight":-0.2657},{"period":"3month","weight":-0.1586},{"period":"6month","weight":0.0804},{"period":"1year","weight":0.0728},{"period":"ytd","weight":-0.0394}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"27467人(较上一季度减少0.20%)","perCapita":"51137股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}